Background: Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by skin barrier dysfunction and abnormal immune response. House dust mites (HDM) are a major source of allergens, some of which have cysteine and serine protease activities. Keratinocytes stimulated by HDM-derived proteases have been suggested to contribute to the pathogenesis of AD by producing various cytokines. However, whether keratinocytes contribute to the induction of pruritus in AD, especially by producing pruritus-related mediators upon stimulation with HDM-derived proteases, has not been fully elucidated. Methods: We examined whether the production of endothelin-1 (ET-1), matrix metalloproteinase (MMP)-2, and MMP-9 in keratinocytes can be induced by stimulation with Dermatophagoides farinae extracts, and if so, whether pretreatment with a protease inhibitor or proteinase-activated receptor-2 (PAR-2) antagonist affects the production of these mediators in keratinocytes. Results: Although MMP-2 levels were undetectable in the culture supernatants, the production of ET-1 and MMP-9 was increased upon stimulation with HDM extracts in a concentration- and time-dependent manner and suppressed by pretreatment of HDM extracts with serine protease inhibitor, but not with cysteine protease inhibitor. Mite-derived serine proteases also induced ET-1 and MMP-9 production in a concentration- and time-dependent manner. Moreover, pretreatment with a PAR-2 antagonist inhibited the production of ET-1 and MMP-9 in keratinocytes. Conclusion: These results suggest that the activation of PAR-2 on keratinocytes by HDM-derived serine proteases induces the production of ET-1 and MMP-9, and may contribute to the induction of pruritus in AD.

Keywords:
Atopic dermatitis, House dust mites, Keratinocytes, Endothelin-1, Proteinase-activated receptor-2, Matrix metalloproteinase-9
1.
Leung DY, Bieber T: Atopic dermatitis. Lancet 2003;361:151-160.
2.
Leung DY: Atopic dermatitis: new insights and opportunities for therapeutic intervention. J Allergy Clin Immunol 2000;105:860-876.
3.
Komine M: Analysis of the mechanism for the development of allergic skin inflammation and the application for its treatment: keratinocytes in atopic dermatitis-their pathogenic involvement. J Pharmacol Sci 2009;110:260-264.
4.
Werfel T: The role of leukocytes, keratinocytes, and allergen-specific IgE in the development of atopic dermatitis. J Invest Dermatol 2009;129:1878-1891.
5.
Thomas WR: Hierarchy and molecular properties of house dust mite allergens. Allergol Int 2015;64:304-311.
6.
Scalabrin DM, Bavbek S, Perzanowski MS, Wilson BB, Platts-Mills TA, Wheatley LM: Use of specific IgE in assessing the relevance of fungal and dust mite allergens to atopic dermatitis: a comparison with asthmatic and nonasthmatic control subjects. J Allergy Clin Immunol 1999;104:1273-1279.
7.
Rawle FC, Mitchell EB, Platts-Mills TA: T cell responses to the major allergen from the house dust mite Dermatophagoides pteronyssinus, antigen P1: comparison of patients with asthma, atopic dermatitis, and perennial rhinitis. J Immunol 1984;133:195-201.
8.
Arlian LG, Platts-Mills TA: The biology of dust mites and the remediation of mite allergens in allergic disease. J Allergy Clin Immunol 2001;107:S406-S413.
9.
Thomas WR, Smith WA, Hales BJ, Mills KL, O'Brien RM: Characterization and immunobiology of house dust mite allergens. Int Arch Allergy Immunol 2002;129:1-18.
10.
Rattenholl A, Steinhoff M: Proteinase-activated receptor-2 in the skin: receptor expression, activation and function during health and disease. Drug News Perspect 2008;21:369-381.
11.
Steinhoff M, Corvera CU, Thoma MS, Kong W, McAlpine BE, Caughey GH, Ansel JC, Bunnett NW: Proteinase-activated receptor-2 in human skin: tissue distribution and activation of keratinocytes by mast cell tryptase. Exp Dermatol 1999;8:282-294.
12.
Buddenkotte J, Stroh C, Engels IH, Moormann C, Shpacovitch VM, Seeliger S, Vergnolle N, Vestweber D, Luger TA, Schulze-Osthoff K, Steinhoff M: Agonists of proteinase-activated receptor-2 stimulate upregulation of intercellular cell adhesion molecule-1 in primary human keratinocytes via activation of NF-kappa B. J Invest Dermatol 2005;124:38-45.
13.
Kato T, Takai T, Fujimura T, Matsuoka H, Ogawa T, Murayama K, Ishii A, Ikeda S, Okumura K, Ogawa H: Mite serine protease activates protease-activated receptor-2 and induces cytokine release in human keratinocytes. Allergy 2009;64:1366-1374.
14.
Wilson SR, Thé L, Batia LM, Beattie K, Katibah GE, McClain SP, Pellegrino M, Estandian DM, Bautista DM: The epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to induce itch. Cell 2013;155:285-295.
15.
Bhagwat SS, Larsen AK, Winberg JO, Seternes OM, Bang BE: Salmon and king crab trypsin stimulate interleukin-8 and matrix metalloproteinases via protease-activated receptor-2 in the skin keratinocytic HaCaT cell line. Food Chem Toxicol 2014;69:303-311.
16.
Ständer S, Steinhoff M: Pathophysiology of pruritus in atopic dermatitis: an overview. Exp Dermatol 2002;11:12-24.
17.
Masaki T: Historical review: endothelin. Trends Pharmacol Sci 2004;25:219-224.
18.
Kido-Nakahara M, Buddenkotte J, Kempkes C, Ikoma A, Cevikbas F, Akiyama T, Nunes F, Seeliger S, Hasdemir B, Mess C, Buhl T, Sulk M, Müller FU, Metze D, Bunnett NW, Bhargava A, Carstens E, Furue M, Steinhoff M: Neural peptidase endothelin-converting enzyme 1 regulates endothelin 1-induced pruritus. J Clin Invest 2014;124:2683-2695.
19.
Aktar MK, Kido-Nakahara M, Furue M, Nakahara T: Mutual upregulation of endothelin-1 and IL-25 in atopic dermatitis: Allergy 2015;70:846-854.
20.
Yohn JJ, Morelli JG, Walchak SJ, Rundell KB, Norris DA, Zamora MR: Cultured human keratinocytes synthesize and secrete endothelin-1. J Invest Dermatol 1993;100:23-26.
21.
Gschwandtner M, Purwar R, Wittmann M, Bäumer W, Kietzmann M, Werfel T, Gutzmer R: Histamine upregulates keratinocyte MMP-9 production via the histamine H1 receptor. J Invest Dermatol 2008;128:2783-2791.
22.
Purwar R, Kraus M, Werfel T, Wittmann M: Modulation of keratinocyte-derived MMP-9 by IL-13: a possible role for the pathogenesis of epidermal inflammation. J Invest Dermatol 2008;128:59-66.
23.
Harper JI, Godwin H, Green A, Wilkes LE, Holden NJ, Moffatt M, Cookson WO, Layton G, Chandler S: A study of matrix metalloproteinase expression and activity in atopic dermatitis using a novel skin wash sampling assay for functional biomarker analysis. Br J Dermatol 2010;162:397-403.
24.
Giannelli G, Foti C, Marinosci F, Bonamonte D, Antonaci S, Angelini G: Gelatinase expression at positive patch test reactions. Contact Dermatitis 2002;46:280-285.
25.
Shubayev VI, Myers RR: Matrix metalloproteinase-9 promotes nerve growth factor-induced neurite elongation but not new sprout formation in vitro. J Neurosci Res 2004;77:229-239.
26.
Tominaga M, Kamo A, Tengara S, Ogawa H, Takamori K: In vitro model for penetration of sensory nerve fibres on a Matrigel basement membrane: implications for possible application to intractable pruritus. Br J Dermatol 2009;161:1028-1037.
27.
Sugiura H, Omoto M, Hirota Y, Danno K, Uehara M: Density and fine structure of peripheral nerves in various skin lesions of atopic dermatitis. Arch Dermatol Res 1997;289:125-131.
28.
Tobin D, Nabarro G, Baart de la Faille H, van Vloten WA, van der Putte SC, Schuurman HJ: Increased number of immunoreactive nerve fibers in atopic dermatitis. J Allergy Clin Immunol 1992;90:613-622.
29.
Tominaga M, Takamori K: Itch and nerve fibers with special reference to atopic dermatitis: therapeutic implications. J Dermatol 2014;41:205-212.
30.
Lee SE, Kim JM, Jeong SK, Jeon JE, Yoon HJ, Jeong MK, Lee SH: Protease-activated receptor-2 mediates the expression of inflammatory cytokines, antimicrobial peptides, and matrix metalloproteinases in keratinocytes in response to Propionibacterium acnes. Arch Dermatol Res 2010;302:745-756.
31.
Tsybikov NN, Petrisheva IV, Kuznik BI, Magen E: Plasma endothelin-1 levels during exacerbation of atopic dermatitis. Allergy Asthma Proc 2015;36:320-324.
32.
Page-McCaw A, Ewald AJ, Werb Z: Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol 2007;8:221-233.
33.
Devillers AC, van Toorenenbergen AW, Klein Heerenbrink GJ, Muldert PG, Oranje AP: Elevated levels of plasma matrix metalloproteinase-9 in patients with atopic dermatitis: a pilot study. Clin Exp Dermatol 2007;32:311-313.
34.
Sun G, Stacey MA, Schmidt M, Mori L, Mattoli S: Interaction of mite allergens Der p3 and Der p9 with protease-activated receptor-2 expressed by lung epithelial cells. J Immunol 2001;167:1014-1021.
35.
Tsuboi R, Sato C, Shi CM, Nakamura T, Sakurai T, Ogawa H: Endothelin-1 acts as an autocrine growth factor for normal human keratinocytes. J Cell Physiol 1994;159:213-220.
36.
Sah SK, Kim BH, Park GT, Kim S, Jang KH, Jeon JE, Shin J, Kim TY: Novel isonahocol E(3) exhibits anti-inflammatory and anti-angiogenic effects in endothelin-1-stimulated human keratinocytes. Eur J Pharmacol 2013;720:205-211.
37.
Khurram SA, Bingle L, McCabe BM, Farthing PM, Whawell SA: The chemokine receptors CXCR1 and CXCR2 regulate oral cancer cell behaviour. J Oral Pathol Med 2014;43:667-674.
38.
Carvalho RF, Nilsson G, Harvima IT: Increased mast cell expression of PAR-2 in skin inflammatory diseases and release of IL-8 upon PAR-2 activation. Exp Dermatol 2010;19:117-122.
39.
Moormann C, Artuc M, Pohl E, Varga G, Buddenkotte J, Vergnolle N, Brehler R, Henz BM, Schneider SW, Luger TA, Steinhoff M: Functional characterization and expression analysis of the proteinase-activated receptor-2 in human cutaneous mast cells. J Invest Dermatol 2006;126:746-755.
40.
Kanda N, Watanabe S: Histamine enhances the production of nerve growth factor in human keratinocytes. J Invest Dermatol 2003;121:570-577.
41.
Kinkelin I, Mötzing S, Koltenzenburg M, Bröcker EB: Increase in NGF content and nerve fiber sprouting in human allergic contact eczema. Cell Tissue Res 2000;302:31-37.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.